Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab versus mycophenolate mofetil in moderate-to-severe pemphigus vulgaris
MOH_2017-01-04_000025Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rituximab and mycophenolate mofetil in pemphigus vulgaris (PV) (2 arms), sponsored by Roche. Started Jan 2015; status: completed.
02
Drugs
rituximabmycophenolate mofetil
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on MOH_2017-01-04_000025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-01-04_000025.